313 related articles for article (PubMed ID: 17192406)
1. Proline-, glutamic acid-, and leucine-rich protein-1/modulator of nongenomic activity of estrogen receptor enhances androgen receptor functions through LIM-only coactivator, four-and-a-half LIM-only protein 2.
Nair SS; Guo Z; Mueller JM; Koochekpour S; Qiu Y; Tekmal RR; Schüle R; Kung HJ; Kumar R; Vadlamudi RK
Mol Endocrinol; 2007 Mar; 21(3):613-24. PubMed ID: 17192406
[TBL] [Abstract][Full Text] [Related]
2. Proline-, glutamic acid-, and leucine-rich protein-1 is essential in growth factor regulation of signal transducers and activators of transcription 3 activation.
Manavathi B; Nair SS; Wang RA; Kumar R; Vadlamudi RK
Cancer Res; 2005 Jul; 65(13):5571-7. PubMed ID: 15994929
[TBL] [Abstract][Full Text] [Related]
3. Regulation of the transcriptional coactivator FHL2 licenses activation of the androgen receptor in castrate-resistant prostate cancer.
McGrath MJ; Binge LC; Sriratana A; Wang H; Robinson PA; Pook D; Fedele CG; Brown S; Dyson JM; Cottle DL; Cowling BS; Niranjan B; Risbridger GP; Mitchell CA
Cancer Res; 2013 Aug; 73(16):5066-79. PubMed ID: 23801747
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic potential of the nuclear receptor coregulator proline-, glutamic acid-, leucine-rich protein 1/modulator of the nongenomic actions of the estrogen receptor.
Rajhans R; Nair S; Holden AH; Kumar R; Tekmal RR; Vadlamudi RK
Cancer Res; 2007 Jun; 67(11):5505-12. PubMed ID: 17545633
[TBL] [Abstract][Full Text] [Related]
5. Interaction and functional cooperation between the LIM protein FHL2, CBP/p300, and beta-catenin.
Labalette C; Renard CA; Neuveut C; Buendia MA; Wei Y
Mol Cell Biol; 2004 Dec; 24(24):10689-702. PubMed ID: 15572674
[TBL] [Abstract][Full Text] [Related]
6. Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence.
Kahl P; Gullotti L; Heukamp LC; Wolf S; Friedrichs N; Vorreuther R; Solleder G; Bastian PJ; Ellinger J; Metzger E; Schüle R; Buettner R
Cancer Res; 2006 Dec; 66(23):11341-7. PubMed ID: 17145880
[TBL] [Abstract][Full Text] [Related]
7. Modulation of aryl hydrocarbon receptor activity by four and a half LIM domain 2.
Kollara A; Brown TJ
Int J Biochem Cell Biol; 2009 May; 41(5):1182-8. PubMed ID: 19015043
[TBL] [Abstract][Full Text] [Related]
8. Functional and biological properties of the nuclear receptor coregulator PELP1/MNAR.
Vadlamudi RK; Kumar R
Nucl Recept Signal; 2007 May; 5():e004. PubMed ID: 17525794
[TBL] [Abstract][Full Text] [Related]
9. Functional implications of altered subcellular localization of PELP1 in breast cancer cells.
Vadlamudi RK; Manavathi B; Balasenthil S; Nair SS; Yang Z; Sahin AA; Kumar R
Cancer Res; 2005 Sep; 65(17):7724-32. PubMed ID: 16140940
[TBL] [Abstract][Full Text] [Related]
10. Androgen induction of the androgen receptor coactivator four and a half LIM domain protein-2: evidence for a role for serum response factor in prostate cancer.
Heemers HV; Regan KM; Dehm SM; Tindall DJ
Cancer Res; 2007 Nov; 67(21):10592-9. PubMed ID: 17975004
[TBL] [Abstract][Full Text] [Related]
11. Four and a half LIM domain 2 alters the impact of aryl hydrocarbon receptor on androgen receptor transcriptional activity.
Kollara A; Brown TJ
J Steroid Biochem Mol Biol; 2010 Jan; 118(1-2):51-8. PubMed ID: 19815066
[TBL] [Abstract][Full Text] [Related]
12. FHL2, a novel tissue-specific coactivator of the androgen receptor.
Müller JM; Isele U; Metzger E; Rempel A; Moser M; Pscherer A; Breyer T; Holubarsch C; Buettner R; Schüle R
EMBO J; 2000 Feb; 19(3):359-69. PubMed ID: 10654935
[TBL] [Abstract][Full Text] [Related]
13. PELP1: a review of PELP1 interactions, signaling, and biology.
Girard BJ; Daniel AR; Lange CA; Ostrander JH
Mol Cell Endocrinol; 2014 Jan; 382(1):642-651. PubMed ID: 23933151
[TBL] [Abstract][Full Text] [Related]
14. Deregulation of estrogen receptor coactivator proline-, glutamic acid-, and leucine-rich protein-1/modulator of nongenomic activity of estrogen receptor in human endometrial tumors.
Vadlamudi RK; Balasenthil S; Broaddus RR; Gustafsson JA; Kumar R
J Clin Endocrinol Metab; 2004 Dec; 89(12):6130-8. PubMed ID: 15579769
[TBL] [Abstract][Full Text] [Related]
15. The LIM-only protein FHL2 is a serum-inducible transcriptional coactivator of AP-1.
Morlon A; Sassone-Corsi P
Proc Natl Acad Sci U S A; 2003 Apr; 100(7):3977-82. PubMed ID: 12644711
[TBL] [Abstract][Full Text] [Related]
16. Emerging significance of ER-coregulator PELP1/MNAR in cancer.
Nair S; Vadlamudi RK
Histol Histopathol; 2007 Jan; 22(1):91-6. PubMed ID: 17128415
[TBL] [Abstract][Full Text] [Related]
17. The LIM domain protein FHL2 interacts with the NR5A family of nuclear receptors and CREB to activate the inhibin-α subunit gene in ovarian granulosa cells.
Matulis CK; Mayo KE
Mol Endocrinol; 2012 Aug; 26(8):1278-90. PubMed ID: 22734036
[TBL] [Abstract][Full Text] [Related]
18. FHL2, UBC9, and PIAS1 are novel estrogen receptor alpha-interacting proteins.
Kobayashi S; Shibata H; Yokota K; Suda N; Murai A; Kurihara I; Saito I; Saruta T
Endocr Res; 2004 Nov; 30(4):617-21. PubMed ID: 15666801
[TBL] [Abstract][Full Text] [Related]
19. Identification of the LIM protein FHL2 as a coactivator of beta-catenin.
Wei Y; Renard CA; Labalette C; Wu Y; Lévy L; Neuveut C; Prieur X; Flajolet M; Prigent S; Buendia MA
J Biol Chem; 2003 Feb; 278(7):5188-94. PubMed ID: 12466281
[TBL] [Abstract][Full Text] [Related]
20. BRCA1 interacts with FHL2 and enhances FHL2 transactivation function.
Yan J; Zhu J; Zhong H; Lu Q; Huang C; Ye Q
FEBS Lett; 2003 Oct; 553(1-2):183-9. PubMed ID: 14550570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
